

# **Product datasheet for TL314990V**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **ACOX1 Human shRNA Lentiviral Particle (Locus ID 51)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** ACOX1 Human shRNA Lentiviral Particle (Locus ID 51)

Locus ID: 51

Synonyms: ACOX; MITCH; PALMCOX; SCOX

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** ACOX1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001185039, NM 004035, NM 007292, NM 004035.1, NM 004035.2, NM 004035.3,

NM 004035.4, NM 004035.5, NM 004035.6, NM 007292.1, NM 007292.2, NM 007292.3,

NM 007292.4, NM 007292.5, NM 001185039.1, BC008767, BC008767.2, BC010425,

NM 001185039.2, NM 007292.6, NM 004035.7

UniProt ID: Q15067

**Summary:** The protein encoded by this gene is the first enzyme of the fatty acid beta-oxidation pathway,

which catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs. It donates electrons directly to molecular oxygen, thereby producing hydrogen peroxide. Defects in this gene result in pseudoneonatal adrenoleukodystrophy, a disease that is characterized by

accumulation of very long chain fatty acids. Alternatively spliced transcript variants encoding

different isoforms have been identified. [provided by RefSeg, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.



## ACOX1 Human shRNA Lentiviral Particle (Locus ID 51) - TL314990V

# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).